Cytokinetics | CYTK - Operating Profit

Stock Price
65.32
Daily Change
-0.16 -0.24%
Monthly
4.70%
Yearly
61.56%
Q2 Forecast
63.92

Cytokinetics reported $-178.37M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arca Biopharma USD -34.43M 326K Dec/2025
Bayer EUR 1.11B 1.65B Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Exelixis USD 235.91M 20.45M Dec/2025
Geron USD -10.79M 3.1M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Ligand Pharmaceuticals USD 158.89M 149.17M Sep/2025
Merck USD 6.24B 318M Dec/2025
Novartis USD 4.06B 437M Dec/2025
Pfizer USD 4.65B 3.99B Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026